NEW YORK, April 27, 2017 /PRNewswire/ --
Research reports have been issued by Stock-Callers.com on Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), Chimerix Inc. (NASDAQ: CMRX), Coherus Biosciences Inc. (NASDAQ: CHRS), and Omeros Corp. (NASDAQ: OMER). These companies belong to the Biotechnology industry, which is focused on novel drug development and clinical research aimed at treating diseases and medical conditions. These stocks research reports can be downloaded now by simply registering for free at:
Novato, California headquartered Ultragenyx Pharmaceutical Inc.'s stock finished Wednesday's session 1.02% higher at $65.68 with a total trading volume of 353,556 shares. The stock is trading below their 200-day moving average by 6.13%. Shares of the Company, which focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the US, have a Relative Strength Index (RSI) of 48.98.
On April 18th, 2017, Ultragenyx Pharmaceutical, Kyowa Hakko Kirin Co., Ltd, and Kyowa Kirin International PLC announced positive 24-week data from the randomized, double-blind, placebo-controlled Phase 3 study of burosumab (KRN23) in adults with X-linked hypophosphatemia. Patients treated with burosumab demonstrated a statistically significant improvement in serum phosphorus levels, with 94% of patients achieving normal levels compared to 8% on placebo.
On April 19th, 2017, research firm Wedbush downgraded the Company's stock rating from 'Outperform' to 'Neutral' while revising its previous target price from $80 a share to $75 a share. Your complete research report on RARE can be retrieved for free at:
Shares in Durham, North Carolina headquartered Chimerix Inc. declined 0.16%, ending yesterday's session at $6.09 with a total trading volume of 254,563 shares. The stock has gained 14.26% in the previous three months and 32.39% on an YTD basis. The Company's shares are trading 1.17% above their 50-day moving average and 19.85% above their 200-day moving average. Moreover, shares of Chimerix, which discovers, develops, and commercializes medicines that address unmet medical needs in the US, have an RSI of 55.79.
On April 20th, 2017, Chimerix announced that it will host its annual investor update event on Thursday, April 27th, 2017, from 4:30 p.m. to 6:30 p.m. ET. Garrett Nichols, MD, MS, Chimerix's Chief Medical Officer, will provide details and timelines on the Company's planned AdAPT trial (Study 999) of short-course oral brincidofovir for the treatment of adenovirus infection. A free report on CMRX is just a click away at:
On Wednesday, Redwood City, California headquartered Coherus Biosciences Inc.'s stock closed flat at $20.15. A total volume of 368,006 shares was traded. The Company's shares are trading 7.04% below their 50-day moving average. Additionally, shares of Coherus Biosciences, which focuses on developing and commercializing biosimilar products worldwide, have an RSI of 50.18.
On April 25th, 2017, Coherus Biosciences announced that it completed the initial phases of the Biologics Price Competition and Innovation Act patent exchange procedure with Amgen for Coherus' Neulasta (pegfilgrastim) biosimilar candidate, CHS-1701. Of the two patents originally listed by Amgen in the process, the parties have reached agreement on a single patent for potential litigation, US patent 8,273,707 (the '707 patent), directed to a method for purifying the product. Sign up for your complimentary research report on CHRS at:
Shares in Seattle, Washington-based Omeros Corp. ended the day 2.26% higher at $16.29. A total volume of 464,632 shares was traded. The stock has gained 28.57% in the last one month, 71.11% in the previous three months, and 64.21% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 22.88% and 44.71%, respectively. Furthermore, shares of Omeros, which discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system, have an RSI of 62.24.
On March 30th, 2017, Omeros announced additional positive data from its Phase-2 clinical trial of OMS721 for the treatment of serious kidney disorders, which frequently lead to end-stage renal disease and dialysis. The clinical trial data include results from additional study patients treated with OMS721 as well as longer-term follow-up on earlier enrolled patients. The new data corroborate and expand on trial results reported in Q4 2016. Register for free on Stock-Callers.com and download the latest research report on OMER at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA